The next step in the authorisation procedure is for ECHA to propose to the European Commission which substances should be prioritised for inclusion into the authorisation list. On the 18th of November 2015 HHPA and MHHPA were included in the draft recommendation for inclusion in the authorisation list. This draft recommendation was open for public consultation until the 18th of February. The ECHA member state committee, comprising of delegates from all national competent authorities, will now discuss this prioritisation and are expected to provide their opinion on October 2016.